Company / Free Cash Flow
Cartesian Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$32.8M
FY2025
5-year range
-$61.5M / $34.1M
FY2021-FY2025
Trend
+36.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 8 years, ranging from -$61M in FY2023 to $34M in FY2022.
Based on SEC 10-K filings.
-$33M in FY2025.
Improved from -$61M to -$33M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 36.2% year-over-year.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$32.8M | +36.2% |
| FY2024 | -$51.4M | +16.4% |
| FY2023 | -$61.5M | -280.4% |
| FY2022 | $34.1M | +166.2% |
| FY2021 | -$51.5M | +14.3% |
| FY2020 | -$60.0M | -13.8% |
| FY2019 | -$52.8M | -308.6% |
| FY2016 | -$12.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026